Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, Beam is the first company to pursue development of new therapies using CRISPR base editing technology. Beam aims to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point…
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Their proprietary ON-OFF switches and synthetic Notch receptors provide T-cells with a far greater capability to recognize cancer and other disease tissues in a precise and controlled manner. This new toolkit for cellular engineering…
Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize treatment of genetically driven disease.
Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly “search and replace” to restore normal genetic function and address the fundamental causes of disease. Prime Medicine envisions a world where Prime Editing can cure, halt, and ultimately prevent genetic diseases, providing…
ReCode Therapeutics is a startup developing novel treatments for genetic lung diseases like cystic fibrosis and primary ciliary dyskinesia. ReCode Therapeutics was formed by combining two companies, Transcriptx and ReCode Therapeutics, that were developing the mRNA and lipid nanoparticle technology respectively. The combined entity, ReCode Therapeutics, has a more expanded focus on genetic diseases with…
Sana Biotechnology is creating and delivering engineered cells as medicine for patients. The company was founded in 2016 by world-renowned scientific founders including Chad Cowan of Harvard, Sonja Schrepfer of UC San Francisco, Chuck Murry of UW, Richard Mulligan of Harvard, David Baker of UW and HHMI, and the scientific team at Flagship Labs led…
Vanqua Bio is an early-stage therapeutics company developing potential disease-modifying treatments for multiple neurodegenerative diseases including Parkinson’s Disease and Lewy Body Dementia. They are utilizing a carefully-designed, scientifically rigorous screening platform to select their drug candidates. The company was founded by The Silverstein Foundation and Orbimed in 2016, with IP from Northwestern University.